secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2026-07-27T20:35:10+00:00
Accession:  0001104659-26-087110
Event type: litigation
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS loses arbitration against 3D Medicines; cash $138.3M as of June 30
-------------------------------------------------------------------------

- Arbitration claims dismissed; company ordered to pay ~$1.0M in legal fees.
- 3D Medicines to continue GPS development; $191.5M in potential milestones remain, including $13.0M disputed.
- Preliminary unaudited cash and equivalents $138.3M as of June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465926087110/0001104659-26-087110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465926087110/tm2621415d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-087110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer